Dr. John Cush RheumNow
2 years 1 month ago
MTX was tapered or D/C in 30% of RA pts w/in 2 yrs of b/tsDMARD Rx. Of 889 pts, MTX (19 mg/wk) tapered in 13.8% & D/C 16.5% (planned taper(37%); pt decision (27.2%). In 582 (66%) MTX unchanged, 4.25 increased MTX after b/tsDMARD initiation https://t.co/yc8exMbeD1 https://t.co/b3L3Fha7xU
Dr. John Cush RheumNow
2 years 1 month ago
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V
Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder.
Dr. John Cush RheumNow
2 years 1 month ago
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?
Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.
https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk
Dr. John Cush RheumNow
2 years 1 month ago
Cost-Effectiveness of Biosimilars vs Leflunomide
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar DMARDs were cost-effective compared with the conventional DMARD, leflunomide.
https://t.co/lWJB1VL1CL https://t.co/lzra8suVqs
Dr. John Cush RheumNow
2 years 1 month ago
IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint space narrowing (JSN). In 222 Knee OA pts, after 7 yrs F/U, ZA had more TKR (39% vs 30%; HR 4.2' 1.2-14.7) https://t.co/2cGeqz2Rwu https://t.co/1UiODwQiK6
Among women followed for upwards of 25 years, those who ate relatively large amounts of "ultraprocessed" foods -- such as soft drinks, frozen pizzas, and mass-produced baked goods -- developed systemic lupus erythematosus at more than 50% greater rates than those with relatively low consumption, a new analysis of Nurses' Health Study data showed.
Dr. John Cush RheumNow
2 years 1 month ago
ICYMI: Can Mycophenolate be Stopped in Stable SLE?
https://t.co/WJv2CajgW9 https://t.co/AU8X5bVSJQ
Dr. John Cush RheumNow
2 years 1 month ago
CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did not prevent (6.3% vs 6.5%; HR 0.98; 0.83 to 1.16) subsequent stroke within 90 days compared with placebo https://t.co/APiMYVkBTV https://t.co/VgFiCKfMqB
Dr. John Cush RheumNow
2 years 1 month ago
ICYMI: Dead Words Eulogy
https://t.co/kmgWJDMigE https://t.co/raZvkGW4vv
Dr. John Cush RheumNow
2 years 1 month ago
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw
Dr. John Cush RheumNow
2 years 1 month ago
5 yr results of 150 difficult-to-treat RA pts - D2T RA resolved in 45%, persisted in 50%, & 5% died. Resolved D2T RA was signif younger, had more Rx changes, & more IL-6i use. Mortality predicted by comorbidity index, steroid escalation (OR 3.50; & 32) https://t.co/cIUNcQ0r3F https://t.co/rNZaWu3Ocd
Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial.
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis (RA) patients with chronic kidney disease (CKD), shows the 3 year survicval to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.
